ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial @MeTherapeutics #Chemicals #Biotechnology #CSEStocks #SmallCaps #Investing
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company has engaged two new clinical consultants to help advance our lead anti-G-CSF antibody candidate (h1B11-12) towards a first in-human clinical trial.Dr. Kate Hanham, PhD, is a clinical trial...
http://dlvr.it/T7YSkz
http://dlvr.it/T7YSkz
Comments
Post a Comment